2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

The study was a controlled trial, which helps in evaluating the efficacy of the new drug in comparison to aspirin. Your doctor or nurse may have given sildenafil abz rezeptfrei you a script for antibiotics to take. It is never selfish to take care of your own health.

Seroquel is a psychopharmacological drug used to treat psychotic disorders with psychotic symptoms,. Haldol, tratado como la droga tricigua para que Catbalogan viagra 100mg 4 stück preisvergleich la comercialización de triciclado se haga en europa, es un remedio poderoso, una droga altamente poderosa tratada psicológicamente. In a small number of patients, both ics/laba and laba/lama combinations may be used.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 692
Format: PDF
Product Code: LMFR0035
Release Date: July and October of 2021
Loading...

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

This report package includes two full reports for the price of one. The reports were released in July and October 2021, respectively. The reports address many of the limitations of conventional therapeutic antibodies and bring you up-to-date on emerging evolutionary antibody technologies:

Vectorized Antibodies for In Vivo Expression by DNA and mRNA

and

Masked Antibodies & Cytokines As Prodrugs

Both reports provide a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective.

Passive immunotherapy with conventional recombinant monoclonal antibodies has become a clinically and commercially extremely successful treatment modality. Breakthroughs in recombinant antibody technologies have resulted in the regulatory approval and commercialization of over 100 monoclonal antibodies (mAbs) to treat a variety of diseases. Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).

Antibody vectorization intends to overcome such limitations of conventional passive immunotherapy. Each of the three different approaches (AAV DNA, plasmid DNA and mRNA) for in vivo expression of antibodies has its specific profile of advantages and disadvantages.

The use of antibody prodrugs is one new strategy for more specific tumor targeting of biological therapies. Conventional prodrugs are pharmacologically inactive compounds that are converted into active forms in the body after administration. They can be designed to be activated at the intended site of action, thereby lowering exposure of normal tissues to active drug and minimizing toxicity.

Detailed report descriptions, tables of contents and sample pages from the full report can be found on the respective product page.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01

Error: Contact form not found.